Table 2.
Main characteristics of the studies included in the meta-analysis.
| Study | Population | Study period | Sample number (patient/control) | Source of miRNA | miRNA expressed | Cancer type/subtype | Histological stage | miRNA analysis platform | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Chen et al., 2017 [22] | China | Jul 2004–Jun 2009 | 165/165 | Tissue (FFPE) | miR-148a | SCC: 45.5%; AC: 54.5% | T1 = 34; T2 = 89; T3 = 41; U = 1 | ISH | 5 yrs |
| Liu et al., 2017 [52] | China | 2003–2005 | 87 | Tissue (FFPE) | miR-29c | AC | T1 = 10; T2 = 62; T3 = 15 | miRNA array/qRT-PCR | 5 yrs |
| Chen et al., 2016 [23] | China | Jan 2010–Jun 2012 | 134 | Tissue (FFPE) | miR-200a | SCC: 41.8%; AC: 48.5%; ASC: 5.2%; LCC: 4.5% | T1 = 34; T2: 26; T3a: 74 | ISH | 28 months (1–58) |
| Wang et al., 2016 [34] | China | Jan 2014–May 2015 | 39/39 | Tissue | miR-148b | SCC: 38.5%; AC: 61.5% | T1 = 12; T2, T3 & T4 = 27 | qRT-PCR | (2–60) months |
| Shang et al., 2016 [53] | China | Jun 2009–Sept 2010 | 139/139 | Tissue | miR-383 | SCC: 59%; AC: 41% | T1 & T2 = 63; T3 = 76 | qRT-PCR | 60 months |
| Chen et al., 2015 [50] | China | Mar 2007–Apr 2013 | 137/137 | Tissue | miR-153 | SCC: 49.6%; AC: 50.4% | T1 & T2 = 104; T3 & T4 = 33 | qRT-PCR | 5 yrs |
| Ge et al., 2015 [35] | China | May 2007–Apr 2012 | 151/151 | Tissue | miR-148b | SCC: 46.4%; AC: 43.7% | T1 & T2 = 91; T3 & T4 = 60 | qRT-PCR | N/A |
| Skrzypski et al., 2014 [30] | Poland | 2001–2012 | 134 | Tissue | miR-662/miR-192/miR-192∗ | SCC | T1a = 29; T1b = 65; T2a = 4 & T2b = 31 & T3a = 5 | miRNA array/qRT-PCR | 5.8 yrs (4.1–10.0) |
| Yu et al., 2014 [13] | China | May 2008–Jul 2010 | 164/164 | Serum | miR-375 | SCC: 26.8%, AC: 60.98%, Others: 12.2% | T1 = 3; T2 = 42; T3 = 58; T4 = 34 | qRT-PCR | 24 months (0–56) |
| 53/53 | Serum | miR-375 | N/A | N/A | qRT-PCR | 24 months (0–56) | |||
| Xiao-chun et al., 2013 [19] | China | 2001–2007 | 60/60 | Tissue | miR-21 | NSCLC | T1 & T2 = 29; T3 & T4 = 31 | qRT-PCR | N/A |
| Sanfiorenzo et al., 2013 [17] | France | Mar 2008–Mar 2010 | 52/20 | Plasma | miR-155 | SCC: 48%; AC: 52% | T1a = 8; T1b = 14; T2a = 5; T2b = 8; T3a = 7 | qRT-PCR | N/A |
| Chen et al., 2013 [33] | China | Feb 2008–Dec 2009 | 47 | Tissue (FFPE) | miR-148a | SCC: 52.1%; AC: 47.9% | T1 = 25; T2 & T3 = 23 | qRT-PCR | N/A |
| Jang et al., 2012 [14] | USA | Jan 1997–Sep 2008 | 56/56 | Tissue (FF) | miR-708 | AC | N/A | miRNA array/qRT-PCR | N/A |
| 47/47 | Tissue (FFPE) | miR-708 | AC | N/A | miRNA array/qRT-PCR | N/A | |||
| Liu et al., 2012 [24] | China | 2003–2005 | 70/70 | Tissue | miR-21 | AC | T1 = 10; T2 = 62; T3 = 15 | miRNA array/qRT-PCR | 2 yrs |
| Li et al., 2012 [51] | China | Jan 2006–Dec 2007 | 96/96 | Tissue | miR-375 | SCC: 43.75%; AC: 56.25% | T1 or T2 = 66; T3 = 30 | qRT-PCR | 30 months (8–69) |
| Tan et al., 2011 [31] | China | 2000–2002 | 60/60 | Tissue | miR-31 | NSCLC | T1 = 21; T2 = 17 & T3 = 22 | miRNA array/qRT-PCR | N/A |
| Donnem et al., 2011 [15] | Norway | 1990–2004 | 191 | Tissue (SCC) | miR-155 | SCC | N/A | ISH | 86 months (48–216) |
| 95 | Tissue (AC) | miR-155 | AC | N/A | ISH | 86 months (48–216) | |||
| Saito et al., 2011 [16] | USA | 1987–2009 | 89/89 | Tissue | miR-21/miR-155 | AC | T1 = 57; t2 = 22; T3 = 10 | qRT-PCR | 5 yrs |
| Norway | 1988–2003 | 37/37 | Tissue | miR-21/miR-155 | AC | T1 = 21; T2 = 5; T3 = 11 | qRT-PCR | 5 yrs | |
| Japan | 1998–2008 | 191/191 | Tissue | miR-21/miR-155 | AC | T1 = 142; T2 = 49 | qRT-PCR | 5 yrs | |
| Wang et al., 2011 [18] | China | 2003–2005 | 88/17 | Serum | miR-21 | SCC: 23.9%, AC: 42%, Others: 34.1% | T1, T2 = 47; T3 = 41 | miRNA array/qRT-PCR | 52.16 months (1–73) |
| Gao et al., 2011 [25] | China | Feb 2004–Jan 2005 | 30/30 | Tissue | miR-21 | SCC | T1 = 17; T2 = 12 & T3 = 13 | miRNA array/qRT-PCR | 4-5 yrs |
| Gao et al., 2010 [26] | China | Apr 2008–Sep 2008 | 47/47 | Tissue | miR-21/miR-181a | SCC: 55.32%; AC: 44.68% | T1 = 22; T2 = 12 & T3 = 13 | miRNA array/qRT-PCR | N/A |
| Voortman et al., 2010 [20] | USA | N/A | 697/79 | Tissue | miR-155/miR-21/miR-let-7/miR-29b/miR-34a/b/c | NSCLC | N/A | qRT-PCR | 8 yrs |
| Raponi et al., 2009 [28] | USA | Oct 1991–Jul 2002 | 61/10 | Tissue | miR-155/mir-146b | SCC | T1: 33; T2–T4 = 28 | qRT-PCR | 3 yrs |
| Markou et al., 2008 [27] | Greece | 2004–2005 | 48/48 | Tissue | miR-21 | SCC: 47.9%; AC: 52.1% | T1 & T2 = 32; T3 & T4 = 16 | qRT-PCR | 39 months |
| Yu et al., 2008 [21] | Taiwan | Sept 2000–Dec 2003 | 112 | Tissue | miR-let-7 | N/A | N/A | miRNA array/qRT-PCR | N/A |
| Yanaihara et al., 2006 [29] | USA | N/A | 104/104 | Tissue | miR-let-7/miR-155 | SCC: 37.5%; AC: 62.5% | T1 = 65; T2 = 17; T3 & T4 = 22 | qRT-PCR | N/A |
| Takamizawa et al., 2004 [32] | Japan | N/A | 143 | Tissue | miR-let-7 | SCC: 17.5%; AC: 73.4%; LCC: 6.3%; ASC: 2.8% | T1 = 71; T2 = 19 & T3 = 49 | qRT-PCR | N/A |
FF: formalin-fixed; FFPE: formalin-fixed paraffin-embedded; AC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large-cell carcinoma; ASC: adeno-squamous carcinoma; NSCLC: non-small-cell lung carcinoma; qRT-PCR: quantitative real time PCR; N/A: not available.